JOHN WILEY & SONS, INC. (WLYB) Market Cap & Valuation Ratios

JOHN WILEY & SONS, INC. (WLYB) has a market cap of $2.8B, a trailing P/E of 14.7 and a price-to-sales ratio of 1.7, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason

WLYBJOHN WILEY & SONS, INC.Follow WLYB — free

Publishing · Communication Services

—

Price chart with a free account

Market cap: 2.8B
P/E TTM: 14.7
Dividend yield: 2.6%
52-week: —
Next earnings: 3 Dec, in 40 days

Peers

publishing · nearest by market cap · trailing 12 months

Company	Mkt cap, $B	P/E	EV/Sales	EV/EBITDA	FCF yield	Rev. growth	Op. margin	ROIC
WLYB	2.8	14.7	2.4	10.0	8.2%	-0.3%	15%	11%
NYT	11	29.0	3.5	18.9	5.6%	+11%	16%	21%
MH	2.8	30.5	2.4	7.9	12.0%	+0.1%	14%	7%
WLY	2.7	14.5	2.4	10.0	8.3%	-0.3%	15%	11%
WBTN	1.3	—	0.5	—	-0.3%	-0.5%	-4%	-7%
TDAY	1.0	—	0.8	6.3	6.1%	-7%	7%	11%
SCHL	0.7	—	0.5	9.4	-2.0%	-3%	1.0%	1%
QUAD	0.5	15.0	0.4	5.2	10.4%	-8%	4%	14%
PMTS	0.3	23.6	0.9	6.9	24.7%	+17%	9%	14%
Median of these 8		23.6	0.9	7.9	7.2%	-0.4%	8%	11%

P/E 14.7 vs. a peer median of 23.6; EV/Sales 2.4 vs. 0.9. WLYB's own P/E sits at the 21st percentile of its history.

Growth vs. price

each dot a company · hover or tap for values

WBTN and TDAY and SCHL have no P/E (earnings not positive) and are left out · hover or tap a dot for values.

JOHN WILEY & SONS, INC. — questions

What is JOHN WILEY & SONS, INC.'s market cap?: $2.8B.
What is JOHN WILEY & SONS, INC.'s P/E ratio?: 14.7 on trailing twelve-month earnings to 2026-07-31.
What is JOHN WILEY & SONS, INC.'s price-to-sales ratio?: 1.7.

Every figure on this page comes from JOHN WILEY & SONS, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.